Gavi, the Vaccine Alliance, has issued a stark warning that significant funding gaps are jeopardizing critical malaria and Human Papillomavirus (HPV) vaccination programs across Africa. The organization estimates that these financial constraints could lead to approximately 600,000 fewer lives saved by the end of the decade. This alert comes as African nations are set to take on greater financial responsibility for these immunization efforts. Starting in the 2026-2030 period, HPV and malaria vaccines, along with other Gavi-supported vaccines, will be financed through country vaccine budgets, with Gavi transferring decision-making power over 90% of its procurement budget directly to national governments. While this shift aims to provide governments with more control and a clearer resource outlook, the current funding shortfalls necessitate difficult prioritization choices. The malaria program alone faces a nearly 30% budget shortfall, forcing a scale-back in support. Experts emphasize that bridging this gap and protecting vulnerable children will require substantial additional domestic and donor financing. Despite these looming challenges, recent years have seen remarkable progress. HPV vaccination has been instrumental in preventing nearly one million cervical cancer deaths in 29 African countries as of 2024, and the number of countries offering the vaccine has surged from 12 to 35 since 2019, with coverage reaching 47% in 2024. Economically, HPV vaccination is projected to generate an estimated $1.8 billion in benefits through reduced treatment costs and increased productivity. Similarly, malaria vaccines, now routinely available in 25 African countries, have demonstrated significant early impact. Over 52 million doses have been delivered since 2023, leading to documented reductions in severe malaria cases, hospital admissions, and child mortality in countries like Kenya, Malawi, Ghana, and Cameroon. Burkina Faso, for instance, has reported a 32% decline in malaria cases between 2024 and 2025 following the introduction of the vaccine alongside other control measures. Gavi aims to reach 50 million children with malaria vaccines by 2030, a goal now under severe threat due to funding limitations. The organization stresses that sustained investment is crucial to maintain momentum, expand vaccine access, and achieve long-term disease elimination goals.